| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| VitB1/Thiamine Vitamin B1 (thiamine) is an essential water-soluble vitamin required for carbohydrate metabolism and mitochondrial energy production. Its active form, thiamine pyrophosphate (TPP), is a cofactor for key enzymes including pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (α-KGDH), and transketolase. In Alzheimer’s disease (AD), thiamine deficiency and reduced activity of thiamine-dependent enzymes have been repeatedly observed in brain tissue. Impaired glucose metabolism is a hallmark of AD (“type 3 diabetes” hypothesis), and thiamine-dependent enzyme dysfunction contributes to mitochondrial impairment, oxidative stress, and neuronal vulnerability. Experimental studies suggest thiamine and lipophilic derivatives (e.g., benfotiamine) may improve glucose metabolism, reduce advanced glycation end products (AGEs), attenuate oxidative stress, and modulate neuroinflammation. Clinical data are mixed but suggest possible benefit in selected populations or with higher-bioavailability derivatives. Benfotiamine is a fat-soluble derivative of vitamin B1 (thiamine) that’s used to support nerve health, glucose metabolism, and potentially brain function, including in conditions like Alzheimer’s disease (AD) and diabetic neuropathy. -fat-soluble form, so may absorb better when taken with a meal containing fat. Condition / Purpose Typical Dose Range Notes Alzheimer’s Disease (AD) 300–600 mg/day Used in clinical trials (e.g., 300 mg twice daily) Diabetic Neuropathy 300–600 mg/day Most common clinical application General Cognitive Support 150–300 mg/day Lower end for maintenance High-dose experimental use 900–1,200 mg/day Occasionally used under supervision in research Alzheimer’s Disease Table: Vitamin B1 (Thiamine)
TSF: P = minimal immediate effect; R = metabolic enzyme activation; G = long-term neuroprotective adaptation. Thiamine vs Benfotiamine Comparison Table
|
| Source: |
| Type: |
| The balance between matrix metalloproteinase-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1), is critical in regulating extracellular matrix remodeling. A high MMP-9/TIMP-1 ratio—reflecting either elevated MMP-9 levels, reduced TIMP-1 levels, or both—has been consistently associated with increased invasiveness, metastasis, and poorer prognosis in multiple cancer types including breast, lung, and colorectal cancers. • This ratio is being explored as a potential biomarker for tumor aggressiveness and may aid in patient stratification, treatment decision-making, and monitoring therapeutic responses. For sepsis: Although both MMP-9 and TIMP-1 levels were found equally elevated in sepsis, a decrease in the MMP-9/TIMP-1 ratio is significantly associated with severity and mortality. |
| - | Trial, | Sepsis, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:264 Target#:1049 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid